Composition for regulating and improving blood glucose
A Bacillus velezensis KMU01-derived composition addresses the limitations of existing diabetes treatments by reducing blood glucose and regulating insulin secretion, providing a safer and more effective therapeutic option.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- KOOKMINBIO CORP
- Filing Date
- 2024-11-25
- Publication Date
- 2026-05-28
AI Technical Summary
Current treatments for metabolic diseases such as diabetes mellitus, including sulfonylureas, biguanides, and thiazolidinedione drugs, suffer from significant side effects and incomplete therapeutic efficacy, necessitating the development of new compositions for blood sugar control and improvement.
A composition comprising the fermentation culture supernatant, concentrate, or dried product of Bacillus velezensis KMU01 strain (previously known as Bacillus polyfermenticus KMU01) is used to regulate insulin secretion and lower fasting blood glucose levels, potentially including dead bacteria or spores, organic acids, and amino acids.
The composition effectively reduces fasting blood glucose levels and regulates serum insulin secretion, offering a safer and more effective alternative to existing treatments by potentially preventing and treating insulin-related complications.
Smart Images

Figure KR2024018703_28052026_PF_FP_ABST